BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       

«Ocular Hypertension

Below is an extended Ocular Hypertension research listing. Click here to return to the Ocular Hypertension main in depth entry.

Recent Publications on Ocular Hypertension:

Retinal p75 and bax overexpression is associated with retinal ganglion cells apoptosis in a rat model of glaucoma.
PURPOSE: The administration of neurotrophins has been clearly demonstrated...
Direct Link
30th August, 2008
CIR, Laboratory of Ophthalmology, University Campus Bio-Medico, Via Alvaro
Pharmacological management of primary open-angle glaucoma: second-line options and beyond. 30th August, 2008
Department of Ophthalmology, Maastricht University Hospital, Maastricht,
Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Purpose: This study aimed to compare the safety and effect on intraocular...
Direct Link
30th August, 2008
Ophthalmology Clinic, UMK Medical College, Bydgoszcz, Poland.
Currents on target intraocular pressure and intraocular pressure fluctuations in glaucoma management. 30th August, 2008
St Luc University Hospital, Universite Catholique de Louvain, Bruxelles,
Intracranial Pressure in Primary Open Angle Glaucoma, Normal Tension Glaucoma, and Ocular Hypertension: A Case Control Study.
Purpose: To compare intracranial pressure (ICP) in subjects with primary...
Direct Link
23rd August, 2008
Ophthalmology, Duke University Eye Center, DUMC Box 3802 , Durham, North
[Day and nights fluctuation of intraocular pressure and blood pressure in glaucoma and non-glaucoma patients] 22nd August, 2008
Clinica I Oftalmologie, Sp. Sf. Spiridon, Iasi.
Changes in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice database.
AIMS: To assess the incremental change in intraocular pressure (IOP)...
Direct Link
21st August, 2008
Cost-effectiveness.
PURPOSE: To examine longitudinally optic disc structure and inner retinal...
Direct Link
20th August, 2008
Loss of melanopsin-containing retinal ganglion cells in a rat glaucoma model. 19th August, 2008
Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University,
Intraocular pressure response to medication in a clinical setting: the Marshfield Clinic Personalized Medicine Research Project.
PURPOSE: To estimate glaucoma and ocular hypertension prevalence and to...
Direct Link
16th August, 2008
Center for Human Genetics, Marshfield Clinic Research Foundation,
Prevalence of ocular surface disease in glaucoma patients.
PURPOSE: To examine the prevalence of ocular surface disease (OSD) in...
Direct Link
16th August, 2008
Department of Ophthalmology, Hamilton Glaucoma Center, University of
alpha 2 macroglobulin is a mediator of retinal ganglion cell death in glaucoma.
Glaucoma is defined as a chronic and progressive optic nerve neuropathy,...
Direct Link
15th August, 2008
Pharmacology & Therapeutics/Oncology, McGill University, Lady Davis
Does peak intraocular pressure measured by water drinking test reflect peak circadian levels? A pilot study.
BACKGROUND: To determine whether there is a correlation between peak...
Direct Link
15th August, 2008
Glaucoma Services, Sydney Hospital and Sydney Eye Hospital, Sydney, New
Morpho-functional follow-up of the optic nerve in treated ocular hypertension: disc morphometry and steady-state pattern electroretinogram.
PURPOSE: To examine longitudinally optic disc structure and inner retinal...
Direct Link
13th August, 2008
Institute of Ophthalmology, Catholic University of Sacred Heart, Rome,
Eye health of priests and novices in rural area. 5th August, 2008
Department of Ophthalmology, Priest Hospital, Bangkok, Thailand.
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional